New Data Emphasizing LivaNova Perceval Valve Durability to be Presented at the American Association for Thoracic Surgery Meeting
Key findings from study at
The retrospective, observational, single-center study included 468 consecutive patients implanted with Perceval between 2007 and 2017:
- Patient mean age was 79, mean EuroSCORE II was 5.0 and STS score was 5.8.
- The majority of the cases treated were all-comers, including emergencies.
- 55% of cases were conducted as part of concomitant procedures, while a high rate of the isolated aortic valve replacement (AVR) cases was carried out through minimally invasive surgery.
This new clinical data folds into the extensive literary evidence already available surrounding the Perceval technology and its use in hospitals around the world.
“The Perceval sutureless valve offers a stable, time-saving and safe surgical result, both in isolated and in combined procedures,” said Prof. Meuris based on the results from his 11-year experience with Perceval. “We observed promising long-term durability given the current low incidence of SVD after 11 years of continued clinical use.”
“It is critical for a distinctive technology such as Perceval to have strong, real life data to back up its success,” said
The presentation by Prof. Meuris, “Sutureless AVR Experience in a Single Centre: 11 Years of Use in 468 Patients,” will take place on
- Session Name: Minimal Surgery and Novel Approaches
- Session Time:
10 - 11:30 a.m.
- Session Location: MTCC, 206AC
- Presentation Time:
11 - 11:15 a.m.
To read the abstract from the presentation, visit the AATS website.
For more information on the Perceval valve, visit www.livanova.com.
Important Safety Information
TOP POTENTIAL SIDE EFFECTS
The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the Perceval prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis.
MRI conditional. For professional use. Please contact us through our website to receive instructions for use containing full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Not approved in all geographies. Consult your labeling.
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs approximately 4,000 employees. LivaNova operates as two businesses: Cardiovascular and Neuromodulation, with operating headquarters in Mirandola (
For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe LivaNova’s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this news release are based on information presently available to
All information in this news release is as of the date of its release.
LivaNova PLC Media Contact
Deanna Wilke, +1 (281) 727-2764
Director, Corporate Communications